2025 Presenting Companies

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

AstronauTx is developing a portfolio of small molecule therapeutics which will restore and enhance the healthy physiology of the brain by boosting the natural physiological mechanisms which support healthy brain function. This novel and orthogonal approach to treating neurodegenerative disease will both improve the symptoms of the disease and prevent the vicious cycle of worsening pathology.

At AviadoBio, we are relentlessly chasing cures by translating groundbreaking science and precision delivery into life-changing medicines for people living with neurological conditions. With our deep understanding of the brain and suite of proprietary gene therapy platforms and delivery technologies, AviadoBio is working to overcome the challenges of delivering the right drug to the right place. Its innovative, neuroanatomy-led approach is designed to maximize the therapeutic potential of gene therapy to halt or potentially reverse neurodegenerative diseases.

Luma Vision, a groundbreaking start-up based in Dublin and Munich, aims to transform healthcare with its innovative navigation and imaging platform for cardiology. LUMA’s mission is to revolutionize cardiac procedures by creating cutting edge hardware, software, and data science solutions that address global clinical needs in arrhythmias and structural heart. Their flagship product, VERAFEYE™, is an innovative, 4D navigation and imaging platform with catheter, advanced digital imaging and deep learning techniques. The platform aims to deliver unprecedented personalised data delivered at the point of therapy. LUMA Vision has raised €37M in funding and secured an additional €10M in prestigious grants.

Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology with a unique design and advanced smart algorithmic control, allows physicians to precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate chronic rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland, with US HQ in Braintree, MA.

Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. For more information, go to www.onerahealth.com

Nobi is the smartest lamp in the world, designed for fall detection, fall prevention and even fall prediction. With its sophisticated AI-model and cutting-edge technology, Nobi offers safety and peace of mind while blending seamlessly into each interior.

Nobi empowers elderly to live at home longer. In care facilities, it supports busy caregivers by taking over repetitive, administrative tasks and summarizing important parameters in one easy form.

The smart lamp also brings caregivers peace of mind by keeping an eye out 24/7, assuring them that immediate help can be provided when a fall occurs.

We believe DDR-targeting therapies can play a significant role in the treatment of malignant disease, and we aim to take advantage of the full range of DDR therapeutic strategies to unlock new opportunities for patients.

VarmX has built an advanced pipeline in bleeding and coagulation disorders, leveraging the cutting-edge research of Professor Pieter Reitsma, a globally recognized authority. VarmX’s lead product, VMX-C001, is a novel, modified recombinant factor X specifically engineered to address critical unmet needs in bleeding management of patients on Factor Xa inhibitors (DOACs). VMX-C001 is in late stage clinical development for the prevention of bleeding in patients undergoing urgent surgery and for the treatment of severe spontaneous bleeding. VarmX is backed by a consortium of renowned investors—EQT Life Sciences, Sound Bioventures, EIC, Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures, and InnovationQuarter

Xeltis is a clinical-stage medicaldevice company with the world first polymer-based technology platform designed
to enable natural restoration of heartvalves and blood vessels in the body. The technology uses patient’s own naturalhealing system to develop a new living functional vascular graft or heart
valve. The novel technology comprises of supramolecular polymers (a Nobel prize
winning discovery) and uses electrospinning manufacturing methods to create a
unique architecture of small diameter vascular grafts and heart valve implants.
Presenting a Multi-Billion Dollar market.

Nua Surgical is a maternal health company which has received global recognition for their patented invention; the SteriCISION C-section Retractor. The device aims to improve access and visualisation during Caesarean Delivery thus reducing risk factors that lead to surgical complications.

ONWARD Medical is a medical technology company creating therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and movement disabilities. Building on more than a decade of scientific discovery, preclinical, and clinical research conducted at leading hospitals, rehabilitation clinics, and neuroscience laboratories, the Company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). For more information, visit ONWD.com.

ReimaginingAntibody Drug Conjugates:
Tubulis generates uniquely matched protein-drug conjugates
through the combination of novel proprietary technologies
and disease-specific biologic insight.
Our goal is to expand the therapeutic potential of antibodydrug
conjugates (ADCs) by increasing design flexibility while
overcoming constraints of toxicity, efficacy and indication.
Tubulis will build new conjugates to fill its pipeline and will
collaborate with partners to usher in a new ADC era and deliver
better outcomes for patients.

Ariceum Therapeutics develops targeted radiopharmaceuticals in cancer.Our lead clinical radiopharmaceutical is 177Lu/225Ac-satoreotide (SS0110), an antagonist of the SSTR2 receptor. Satoreotide is developed as a ‘theranostic’ pair for diagnosis and targeted radionuclide treatment of SCLC and MCC.
Our second product ATT001 is a 123Iodine-radiolabeled PARP inhibitor in Phase 1 in recurrent glioblastoma, an indication of high unmet medical need.
Ariceum intends to expand the development of ATT001 into other fast growing PARP expressing tumours.
In partnership with UCB Pharma, we develop macrocyclic peptides against novel targets to develop first-in-class radiopharmaceuticals expanding our pipeline beyond the lead assets.

PanTera wants to bring new hope to cancer patients by enabling the widespread application of radiopharmaceuticals for precision treatment of tumors.

Our core belief is that these powerful medical tools deserve a central role in oncology for their potential to treat cancers effectively while preserving patient's quality of life. Our focus is on the radiotheranostics field, which facilitates patient-tailored optimization of treatment by tracking the distribution of therapeutic agents in the body. This cutting-edge approach minimizes patient side-effects while enhancing treatment efficacy.

Our vision is to make such personalized nuclear medicine treatments a reality, making them widely available and affordable. To realize this vision, we are establishing a state-of-the-art production facility for actinium-225 (Ac-225) in Mol, Belgium. Our unique production process, employing the photonuclear or ‘gamma’ route, transforms Radium-226 (226Ra) into 225Ra, which in turn decays into Ac-225. This high-purity Ac-225 is then supplied as an Active Product Ingredient (API) to the global pharmaceutical market.

In addition to ensuring quality, we prioritize sustainability. The radium in our process is recycled and reused, emphasizing our commitment to environmentally friendly practices. At PanTera, we are not only supporting the development of the next generation of cancer treatments but also fostering a future where personalized nuclear medicine is the norm.

Nouscom is developing off-the-shelf and personalized viral vector cancer immunotherapies clinically demonstrated to safely and potently harness the power of the immune system. Fully recruited trials include NOUS-209 in randomized Phase 2 trials for MSI solid tumors in combination with pembrolizumab, and a Phase 1b/2 of NOUS-209 monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’. Nouscoms personalized cancer immunotherapy, NOUS-PEV is expected to start randomized Phase 2 trials during 2025. Additionally VAC-85135 was developed, GMP manufactured and exclusively licensed to Janssen Oncology and is a Phase 1 trial for Myeloproliferative Neoplasms.

Founded in 2016, Innovative Molecules is a German biotech focused on the discovery, development and commercialization of novel antiviral agents in the field of herpes-mediated diseases.

While there has not been much medical improvement in the treatment of Herpes simplex disease over decades, Innovative Molecules aims to deliver a much more effective treatment than current standard-of-care for patients suffering from genital herpes.

Our lead compound, IM-250 or Adibelivir, is currently tested in a Ph1b/Ph2a study. The oral form of Adibelivir will be developed for the treatment of an episode as well as an effective treatment for the suppression of the disease. An iv formulation of Adibelivir will be developed for the treatment of life-threatening conditions such as herpes encephalitis.

Founded in 2018, ATB Therapeutics is a pioneering biotechnology company based in Marche-en-Famenne, Belgium, dedicated to the discovery and development of novel antibody therapies. Leveraging a proprietary technology platform based on plant molecular farming, ATB Therapeutics aims to deliver targeted solutions to high unmet medical needs, including oncology and autoimmune diseases, through innovative, next-generation of weaponized antibody treatments.

Agomab is focused on achieving disease modification by modulating fibrosis and regeneration in chronic indications such as fibrostenosing Crohn’s disease and idiopathic pulmonary fibrosis. We do this by targeting biologically validated pathways - including Transforming Growth Factor β and Hepatocyte Growth Factor - and by applying specialized capabilities in organ-restricted small molecules and high affinity antibodies. With a differentiated clinical pipeline across several fibrotic disorders, end-to-end research and development capabilities, a proven BD track-record and a strong investor base, Agomab is building a leading biopharma company.

Atalanta Therapeutics is a biotechnology company developing treatments for intractable diseases of the central nervous system using RNA interference. Atalanta’s unique platform of divalent small interfering RNA (di-siRNA) enables durable, selective gene silencing throughout the brain and spinal cord. Atalanta is advancing a wholly owned pipeline of disease-modifying programs for Huntington’s disease, genetic epilepsy, severe chronic pain, and other neurological diseases in addition to partnered programs. Atalanta is headquartered in Boston, Mass. For more information, visit www.atalantatx.com.

We are an Amsterdam-based biotech company founded in 2020 with a mission to develop vectorized antibody treatments for people with neurodegenerative diseases, enabling longer, better lives.

Antibody treatments have wide applicability in neurodegenerative diseases that are known to be complex and difficult to treat. Our cutting-edge vectorized antibody technology combines highly selective therapeutic antibodies with one-time AAV-based delivery to the CNS. We are advancing a development pipeline of potentially disease-modifying treatments for ALS, Huntington's frontal temporal dementia and other CNS indications.

Muna Therapeutics is a soon-to-be clinical stage global biotech company based in Denmark, Belgium and the US. We discover and develop disease-modifying medicines that modulate neuroimmune interactions for neurodegenerative and autoimmune diseases. 
Muna's most advanced portfolio program, a best-in-class, orally bioavailable, small molecule TREM2 agonist for early stagy AD, is in IND enabling studies for Ph1 initiation in mid-2025.

Muna's first-in-class, potent, selective brain exposed and peripherally restricted Kv1.3 blockers abrogate chronic inflammation in MS, PD and other disorders, projecting Ph1 by late 2025. 

Muna's newest program is the first resilience target identified by the discovery platform MiND-MAP initiated in 2024.

Cyted Health is a gastrointestinal health company that has created a minimally-invasive diagnostic platform to detect disease early and save lives. Our technologies are transforming access to digestive health for everyone, everywhere. Cyted’s technology brings earlier and faster diagnoses to more people, helping to detect and monitor those with early cancer and inflammatory diseases.

InVera Medical is a clinical-stage medical device company poised to transform the treatment of chronic venous diseases, including varicose veins and venous ulcers, affecting millions worldwide. We are currently raising €20 million in Series A funding to bring our innovative solution to patients globally.
Our groundbreaking, minimally invasive precise mechanical ablation and chemical infusion device eliminates the need for painful thermal burning or glue-based procedures. By leveraging the body's natural healing processes our treatment offers a safe, effective, and pain-free alternative for patients suffering from debilitating venous conditions.

Tympany Medical has developed Solascope, an endoscope designed to enable variable angle visualisation via a rotation portion to the tip – an innovative mechanism for use in complex rhinology cases. Solascope is at the cutting edge of surgical imaging and technology, and aims to assist surgeons in addressing the growing number of sinus surgeries and associated symptoms globally. With multi-billion dollar market opportunity for the endoscope platform, the company has raised over €8m in dilutive and non-dilutive funding to date and are currently raising follow on financing. This will secure regulatory approval and clinical use of Solascope.

AC Immune is a Swiss clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diverse pipeline featuring multiple Phase 2 and one Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.

FoRx Therapeutics develops innovative small molecule therapeutics that target DNA Damage Response (DDR) pathways for anti-cancer therapy. Since DNA damage is a hallmark of cancer and requires continuous repair, the company's approach is to inhibit distinct DDR proteins and deprive cancer cells of their repair capability, resulting in the cells' death. The lead program is a highly potent and selective PARG inhibitor, FORX-428, that is in IND-enabling studies. FoRx Therapeutics has 15 employees and is backed by EQT Life Sciences, M Ventures, Omega Funds, Novartis Venture Fund and Pfizer Ventures, having raised a total of 30 million CHF in Seed Financing and 10 million CHF in Bridge Financing.

ImCheck is advancing next-generation cancer immunotherapies that offer superior benefits over existing treatments, as monotherapies or in combination. The company's first-in-class antibodies target butyrophilins, a unique family of immunomodulators that activate multiple immune cells, including gamma-delta T cells. ImCheck's activating antibodies are designed to outperform first-generation checkpoint inhibitors and overcome resistance in combination therapies. Beyond oncology, ImCheck is exploring applications in autoimmune and infectious diseases. Lead candidate ICT01, which is being evaluated in the Phase I/IIa EVICTION trial, demonstrated high efficacy in AML patients across molecular subtypes when combined with azacitidine-venetoclax, as highlighted by impressive data presented at ASH 2024.

Tenpoint Therapeutics Limited is a global, clinical-stage biotech company developing

groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes

paradigm-shifting treatments for ophthalmic indications with the greatest need and global

market potential, including presbyopia, cataracts and geographic atrophy. Its lead asset,

BRIMOCHOLTM PF, is a novel, pupil-modulating therapeutic designed to correct the loss

of near vision associated with presbyopia, a condition that afflicts approximately 2 billion

people globally. BRIMOCHOLTM PF has completed its first Phase 3 pivotal trial (BRIO-I)

and will complete the second pivotal study, BRIO-II, in 2025. This topical ophthalmic is

poised for launch in 2026. Tenpoint’s leadership team includes ophthalmic industry

luminaries with track records of successful approvals and commercialization of

blockbuster drugs. A privately held company, Tenpoint Therapeutics is backed by AdBio

Partners, British Patient Capital, Eight Roads, EQT Life Sciences, F-Prime Capital,

Hillhouse Capital Management, Qiming Venture Partners USA, Sofinnova Partners, and

UCL Technology Fund

INBRAIN develops graphene semiconductors technology to pioneering implantable precision BCI therapeutics at scale for personalized neuro and bioelectronics therapies. Graphene brings unparalleled signal decoding resolution and micrometric modulation precision compared to metals (like platinum and iridium) to drive highly targeted neuro and bioelectronic applications. In bioelectronics we have a strategic collaboration with Merck in very large pharma style indications such as anti-inflammation. In 2024, we announced the world's first application of our BCI interface in a brain cancer procedure able to differentiate healthy from tumoral tissue at micrometric scale. Additionally we got FDA breakthrough designation & TAP for the implantable platform in movement control in Parkinson’s disease. The company has recently closed a $50M round, together with an additional 30M contribution from Merck to advance the platform to chronic human stage. This 80M additional investment, puts INBRAIN in a key position to advance this next generation of Neuroelectronics therapies from EU to the world

AuriGen Medical is clinical stage MedTech company based in Galway, Ireland. AuriGen aims to transform stroke prevention with its innovative Zenith device for Left Atrial Appendage Occlusion (LAAO) by addressing key unmet clinical and market needs related to enhanced safety outcomes and device ease of use. By reducing complexity and enhancing safety, Zenith has the potential to significantly expand the existing user base while also simplifying procedures, offering a more accessible solution for new and existing implanters. AuriGen have completed a early feasibility first in human trial and are now raising €20m in our Series A Investment Round.

INBRAIN Neuroelectronics is a leading company in BCI (Brain-Computer Interface) therapeutics, advancing real-time precision neurology to treat neurological disorders. Founded in 2020 and headquartered in Spain, INBRAIN uses graphene-based neural interfaces to decode brain signals with unparalleled accuracy. These innovative technologies enable personalized, minimally invasive therapies for conditions such as Parkinson’s disease & stroke rehabilitation amongst others. Partnering with industry leaders like Merck, INBRAIN leverages graphene's exceptional biocompatibility, scalability, and energy efficiency to push the boundaries of bioelectronic medicine. Committed to transforming patient care, INBRAIN is redefining the future of neurotechnology and real-time precision therapeutics worldwide.

Kynexis is a biotechnology company focused on developing precision therapeutics for brain diseases. The company is progressing KYN-5356, a novel and selective KAT-II enzyme inhibitor for the treatment of Cognition Impairment Associated with Schizophrenia (CIAS). Recently completed First-in-Human study results confirmed our scientific rationale, that selective inhibition of the KAT-II enzyme with KYN-5356 leads to lower KYNA levels in the CSF and resulted in the activation of relevant neuronal networks (as measured by EEG) and a signal of cognitive improvement. The Phase 2 trial with cognition endpoints is scheduled to start mid-2025